*NOTE - some study locations are open, while others remain temporarily closed due to the impact of Coronavirus (COVID-19)*
If you are interested in taking part in this study, begin typing your location below and then select from the drop-down list. The map will update with sites within the selected distance and a list of locations will appear below.Please note, the map below only lists study sites that are accepting online referrals. If you cannot find a site in your area, please check back again as study sites can be added to the study on an ongoing basis.
Alternatively, if you wish to see the full listing of all study sites, visit clinicaltrials.gov.
| Site Name | Address | Status | Distance | |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | 2940 East Banner Gateway Drive
Gilbert, AZ, 85234 United States |
Recruiting | -- | |
| Earle A. Chiles Research Institute | 4805 Northeast Glisan Street
Portland, OR, 97213 United States |
Recruiting | -- | |
| Intermountain Healthcare- LDS Hospital | 8th Ave and C Street
Salt Lake City, UT, 84143 United States |
Recruiting | -- | |
| Levine Cancer Institute | 1021 Morehead Medical Drive
Charlotte, NC, 28204 United States |
Not Recruiting | -- | |
| New York Oncology Hematology - Albany Cancer Center | 43 New Scotland Ave.
Albany, NY, 12208 United States |
Recruiting | -- | |
| Northwest Medical Specialties | 1624 South I Street
Tacoma, WA, 98405 United States |
Not Recruiting | -- | |
| Northwestern University | 675 North Saint Clair Street
Chicago, IL, 60611 United States |
Recruiting | -- | |
| Oncology Hematology Care | 4725 East Galbraith Road Suite 320
Cincinnati, OH, 45236 United States |
Recruiting | -- | |
| Regional Cancer Care Associates | Brier Hill Court, Bldg. J2
East Brunswick, NJ, 08816 United States |
Recruiting | -- | |
| Stanford Cancer Genetics Clinic | 875 Blake Wilbur Drive
Stanford, CA, 94304 United States |
Recruiting | -- | |
| The Blood and Marrow Transplant Group of Georgia | 5670 Peachtree Dunwoody Rd # 1000
Atlanta, GA, 30342 United States |
Recruiting | -- | |
| USOR - Prisma Health System - Eastside Cancer Center | 65 International Drive
Greenville, SC, 29615 United States |
Recruiting | -- | |
| University of Kentucky | 800 Rose Street
Lexington, KY, 40536 United States |
Recruiting | -- | |
| University of Texas Southwestern Medical Center | 5323 Harry Hines Blvd
Dallas, TX, 75390 United States |
Recruiting | -- |
More about Study Participation
Participation in the PILOT Study lasts approximately two years and includes:
• A screening period that will last up to 14 days, during which your eligibility to participate in the PILOT Study will be confirmed. If you are determined to be eligible, your T cells will be removed (through leukapheresis) and the investigational study treatment will be manufactured. This will take approximately four weeks, but timing varies from patient to patient.
• A pretreatment period that will occur up to seven days before the treatment period. During this time, the study doctor will reconfirm that you are eligible for study participation.
• A treatment period, which will last approximately 35 days.
o You will receive an infusion one time, after which you will be closely monitored for side effects for the next 30 days.
o During this time, you will receive three days of conditioning chemotherapy followed by an infusion of the investigational study treatment
• A posttreatment period, during which you will visit the study site at least eight times before your participation in the study ends. This period will last 23 months.
After completion of two years of assessments in this study, an optional long-term follow-up study for survival, long-term toxicity, and safety will continue as a separate study for up to 15 years after administration of JCAR017 investigational study treatment.
The investigational study treatment used in the PILOT Study is called JCAR017. This drug is the result of a modification to a participant’s own immune cells (T cells) with a chimeric antigen receptor (CAR). These modified T cells, (CAR T cells) may attack the cancer cells and other cells. JCAR017 is administered once as an infusion during the treatment period. As with any medicine, JCAR017 may have side effects. As an investigational study treatment, not all the side effects may be known at this time. Two of the primary side effects that you will be monitored for include cytokine release syndrome and neurotoxicity.